FDA targets regulatory 'gaming' to boost generic competition

08:12 EDT 21 Jun 2017 | BioPharmaDive

While the FDA has no direct role in drug pricing, agency head Scott Gottlieb hopes his planned actions could help address rising costs — at least in part. 

Original Article: FDA targets regulatory 'gaming' to boost generic competition


More From BioPortfolio on "FDA targets regulatory 'gaming' to boost generic competition"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...